‘A concerted industry-government effort’: Strand Therapeutics CEO Jake Becraft on FDA’s IND reform and China
For Jake Becraft, Ph.D., the future of America’s biomedical innovation isn’t just playing out in the lab but is being shaped by industrial policy. In a recent interview with Fierce Biotech, the Strand Therapeutics CEO warned that the U.S. faces a critical choice: either modernize its regulatory framework for early-stage clinical trials or risk losing the capabilities permanently.

For Jake Becraft, Ph.D., the future of America’s biomedical innovation isn’t just playing out in the lab but is being shaped by industrial policy. In a recent interview with Fierce Biotech, the Strand Therapeutics CEO warned that the U.S. faces a critical choice: either modernize its regulatory framework for early-stage clinical trials or risk losing the capabilities permanently.
Source: FiercePharma